4502.T Takeda Pharmaceutical Company Limited
JPXHealthcareAs of 2026-08-07 15:30
Why 4502.T matters now
Takeda Pharmaceutical Company Limited (4502.T) is a Japan stock in Healthcare. The latest InvestLog snapshot shows ¥5,540.00 with +2.12% on the session and ¥8.81T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 48.50, gross margin 62.1%, and operating margin 10.5%.
Valuation
P/E (TTM)
48.50
PEG
—
P/B
1.15
P/S
1.91
EV/EBITDA
10.57
DCF Value
—
FCF Yield
7.9%
Div Yield
3.6%
Margins & Returns
Gross Margin
62.1%
Operating Margin
10.5%
Net Margin
3.9%
ROE
2.4%
ROA
1.2%
ROIC
2.4%
Listing Info
Market
Japan
Exchange
JPX
Currency
JPY
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
JP
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.